MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment.
CDK4/6 inhibitors
biomarker
breast cancer
microRNAs
resistance
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Aug 2021
16 Aug 2021
Historique:
received:
30
06
2021
revised:
07
08
2021
accepted:
11
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have emerged as novel treatment options in the management of advanced or metastatic breast cancer. MicroRNAs are endogenous non-coding 19-22-nucleotide-long RNAs that regulate gene expression in development and tumorigenesis. Herein, we systematically review all microRNAs associated with response to CDK4/6 inhibitors in solid tumors and hematological malignancies. Eligible articles were identified by a search of the MEDLINE and ClinicalTrials.gov databases for the period up to1 January 2021; the algorithm consisted of a predefined combination of the words "microRNAs", "cancer" and "CDK 4/6 inhibitors". Overall, 15 studies were retrieved. Six microRNAs (miR-126, miR-326, miR3613-3p, miR-29b-3p, miR-497 and miR-17-92) were associated with sensitivity to CDK4/6 inhibitors. Conversely, six microRNAs (miR-193b, miR-432-5p, miR-200a, miR-223, Let-7a and miR-21) conferred resistance to treatment with CDK4/6 inhibitors. An additional number of microRNAs (miR-124a, miR9, miR200b and miR-106b) were shown to mediate cellular response to CDK4/6 inhibitors without affecting sensitivity to treatment. Collectively, our review provides evidence that microRNAs could serve as predictive biomarkers for treatment with CDK4/6 inhibitors. Moreover, microRNA-targeted therapy could potentially maximize sensitivity to CDK4/6 inhibition.
Identifiants
pubmed: 34439268
pii: cancers13164114
doi: 10.3390/cancers13164114
pmc: PMC8391635
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Med. 2015 Sep;4(9):1417-25
pubmed: 26129688
J Hepatol. 2014 Mar;60(3):590-8
pubmed: 24211739
Tumour Biol. 2015 Sep;36(9):6725-32
pubmed: 25833695
Cancer Res. 2007 Aug 15;67(16):7713-22
pubmed: 17699775
Cancer Biol Ther. 2014;15(11):1444-55
pubmed: 25482951
Br J Haematol. 2011 Oct;155(1):73-83
pubmed: 21810092
Cancer Res. 2020 Mar 1;80(5):1064-1077
pubmed: 31862778
Br J Cancer. 2020 May;122(11):1630-1637
pubmed: 32238921
J Gen Virol. 2009 May;90(Pt 5):1164-1171
pubmed: 19264608
Drug Des Devel Ther. 2014 Feb 24;8:293-314
pubmed: 24591819
Oncologist. 2015 May;20(5):483-90
pubmed: 25876993
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183020
Gastroenterology. 2009 May;136(5):1689-700
pubmed: 19422085
J Biol Chem. 2008 Oct 31;283(44):29897-903
pubmed: 18708351
EMBO J. 2007 Aug 8;26(15):3699-708
pubmed: 17627278
Cell. 2006 Mar 24;124(6):1169-81
pubmed: 16564011
Endocr Relat Cancer. 2015 Oct;22(5):R279-300
pubmed: 26346768
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Clin Lung Cancer. 2015 Nov;16(6):e121-9
pubmed: 25703099
Clin Cancer Res. 2011 May 1;17(9):3029-38
pubmed: 21248297
Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
J Invest Dermatol. 2017 Sep;137(9):1955-1964
pubmed: 28526299
Mol Cell Biol. 2008 Apr;28(7):2167-74
pubmed: 18212054
PLoS Genet. 2013 Apr;9(4):e1003459
pubmed: 23637628
Cell Mol Life Sci. 2015 Jul;72(13):2575-84
pubmed: 25782411
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Front Genet. 2019 Sep 11;10:815
pubmed: 31572437
Endocr Relat Cancer. 2007 Sep;14(3):791-8
pubmed: 17914108
Cancer Res. 2009 May 15;69(10):4443-53
pubmed: 19435910
Cell Rep. 2019 Mar 5;26(10):2667-2680.e7
pubmed: 30840889
Front Oncol. 2020 Nov 27;10:590813
pubmed: 33330073
Nature. 2005 Dec 1;438(7068):685-9
pubmed: 16258535
Oncotarget. 2014 Mar 15;5(5):1185-97
pubmed: 24727437
Oncotarget. 2017 Jul 21;8(33):55319-55331
pubmed: 28903422
Cancer Cell. 2008 Mar;13(3):272-86
pubmed: 18328430
J Biol Chem. 2007 Aug 10;282(32):23716-24
pubmed: 17569667
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Front Biosci (Landmark Ed). 2012 Jun 01;17:2508-40
pubmed: 22652795
J Exp Clin Cancer Res. 2019 Aug 28;38(1):380
pubmed: 31462285
J Hematol Oncol. 2020 May 1;13(1):41
pubmed: 32357912
Cancer Res. 2010 Jul 15;70(14):6015-25
pubmed: 20610624
Oncogene. 2011 Mar 3;30(9):1082-97
pubmed: 21057537
J Exp Clin Cancer Res. 2011 Feb 17;30:20
pubmed: 21329503
Oncogene. 2008 Sep 25;27(43):5651-61
pubmed: 18521080
Oncogene. 2019 Jun;38(26):5191-5210
pubmed: 30918328
Int J Nanomedicine. 2016 Dec 30;12:217-237
pubmed: 28115844
Front Genet. 2018 May 18;9:174
pubmed: 29868122
Oncotarget. 2014 Feb 28;5(4):944-58
pubmed: 24659709
Mol Cell Biol. 2009 May;29(10):2841-51
pubmed: 19273599
PLoS One. 2008 Mar 26;3(3):e1864
pubmed: 18365017
Blood. 2009 Jan 8;113(2):396-402
pubmed: 18941111
Oncogene. 2006 Apr 20;25(17):2537-45
pubmed: 16331254
PLoS One. 2011 Jan 20;6(1):e16138
pubmed: 21283765
Mol Cancer Ther. 2020 Oct;19(10):2221-2232
pubmed: 32747423
Biochem Pharmacol. 2008 Sep 1;76(5):582-8
pubmed: 18619946
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
J Pathol. 2020 Sep;252(1):77-87
pubmed: 32558936
Int J Nanomedicine. 2016 Dec 12;11:6713-6725
pubmed: 28003747
J Ovarian Res. 2014 Aug 31;7:84
pubmed: 25297343
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Cell Death Dis. 2018 Jan 23;9(2):77
pubmed: 29362401
PLoS Genet. 2015 Dec 30;11(12):e1005748
pubmed: 26716708
Front Genet. 2012 Jul 02;3:120
pubmed: 22783274
Cell. 2009 Jun 12;137(6):1005-17
pubmed: 19524505
Haematologica. 2019 Feb;104(2):347-359
pubmed: 30262555
Gynecol Oncol. 2008 Dec;111(3):478-86
pubmed: 18823650
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Cell Cycle. 2007 Nov 15;6(22):2742-9
pubmed: 17986865
Int J Cancer. 2011 Sep 15;129(6):1362-72
pubmed: 21128241
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Gastroenterology. 2006 Jun;130(7):2113-29
pubmed: 16762633
Eur J Cancer. 2010 Jun;46(9):1692-702
pubmed: 20371173
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
J Hum Genet. 2011 Apr;56(4):270-6
pubmed: 21289630
Cell Cycle. 2007 Aug 15;6(16):2005-9
pubmed: 17721077
FEBS Lett. 2015 Oct 7;589(20 Pt B):3154-64
pubmed: 26363097
Curr Mol Med. 2012 Jan;12(1):27-33
pubmed: 22082479
Cell Death Dis. 2020 Sep 15;11(9):760
pubmed: 32934206
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Cell Cycle. 2013 Jan 1;12(1):98-111
pubmed: 23255112
Int J Cancer. 2019 Sep 1;145(5):1179-1188
pubmed: 30478914